A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer

This is a Phase I, multi-center, multiple ascending dose study to evaluate the clinical safety and immune response of IDC-G305 when injected intramuscularly in patients with unresectable or metastatic cancer. IDC-G305 is an immunotherapy consisting of recombinant NY-ESO-1 antigen and the adjuvant, GLA-SE. The goal is for IDC-G305 to stimulate the body's immune system to fight the spread and growth of cancer for patients whose tumors include the NY-ESO-1 protein. Patients with melanoma, ovarian, renal cell or non-small cell lung cancer may be considered for the trial.

Start Date01 Nov 2013

Sponsor / Collaborator-

100 Clinical Results associated with NY-ESO-1/GLA-SE cancer vaccine(Immune Design Corp.)

100 Translational Medicine associated with NY-ESO-1/GLA-SE cancer vaccine(Immune Design Corp.)

100 Patents (Medical) associated with NY-ESO-1/GLA-SE cancer vaccine(Immune Design Corp.)

Literatures (Medical) associated with NY-ESO-1/GLA-SE cancer vaccine(Immune Design Corp.)

01 Mar 2012·Theoretical and Applied GeneticsQ1 · AGRICULTURAL & FORESTRY SCIENCE

Identification and characterization of a novel powdery mildew resistance gene PmG3M derived from wild emmer wheat, Triticum dicoccoides

Q1 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Marion S. Röder ; Roi Ben-David ; Tzion Fahima ; Bin Zeng ; Weilong Xie ; Assaf Distelfeld ; Amos Dinoor

Powdery mildew, caused by Blumeria graminis f. sp. tritici (Bgt) is one of the most important wheat diseases worldwide. Wild emmer wheat, Triticum turgidum ssp. dicoccoides, the tetraploid ancestor (AABB) of domesticated bread and durum wheat, harbors many important alleles for resistance to various diseases, including powdery mildew. In the current study, two tetraploid wheat mapping populations, derived from a cross between durum wheat (cv. Langdon) and wild emmer wheat (accession G-305-3M), were used to identify and map a novel powdery mildew resistance gene. Wild emmer accession G-305-3M was resistant to all 47 Bgt isolates tested, from Israel and Switzerland. Segregation ratios of F(2) progenies and F(6) recombinant inbred line (RIL) mapping populations, in their reactions to inoculation with Bgt, revealed a Mendelian pattern (3:1 and 1:1, respectively), indicating the role of a single dominant gene derived from T. dicoccoides accession G-305-3M. This gene, temporarily designated PmG3M, was mapped on chromosome 6BL and physically assigned to chromosome deletion bin 6BL-0.70-1.00. The F(2) mapping population was used to construct a genetic map of the PmG3M gene region consisted of six simple sequence repeats (SSR), 11 resistance gene analog (RGA), and two target region amplification polymorphism (TRAP) markers. A second map, constructed based on the F(6) RIL population, using a set of skeleton SSR markers, confirmed the order of loci and distances obtained for the F(2) population. The discovery and mapping of this novel powdery mildew resistance gene emphasize the importance of the wild emmer wheat gene pool as a source for crop improvement.

100 Deals associated with NY-ESO-1/GLA-SE cancer vaccine(Immune Design Corp.)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer	Phase 3	United States	-	01 Nov 2013
Breast Cancer	Phase 3	United States	Immune Design Corp.	01 Nov 2013
Melanoma	Phase 3	United States	-	01 Nov 2013
Melanoma	Phase 3	United States	Immune Design Corp.	01 Nov 2013
Neoplasm Metastasis	Phase 3	United States	-	01 Nov 2013
Non-Small Cell Lung Cancer	Phase 3	United States	Immune Design Corp.	01 Nov 2013
Non-Small Cell Lung Cancer	Phase 3	United States	-	01 Nov 2013
Sarcoma	Phase 3	United States	Immune Design Corp.	01 Nov 2013
Sarcoma	Phase 3	United States	-	01 Nov 2013
Neoplasms	Phase 2	United States	Portage Biotech, Inc.	24 Aug 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

NY-ESO-1/GLA-SE cancer vaccine(Immune Design Corp.)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation